To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
An international consortium of scientists, including an I2BC team, has just deciphered the functioning of FAP (Fatty Acid Photodecarboxylase), a key photoenzyme for the production of biofuels and other high value added molecules. This work, published in Science, was the object of a CEA press release.
Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications.
A study by researchers from I2BC department shows in vitro the effect of mitotic phosphorylation of the BAF protein on its structure and its interactions with DNA and lamina and unveils consequences on genome organization and on mechanisms responsible for progeroid syndromes.
Aloïse Mabondzo, research director, head of the Neurovascular Pharmacology Group of the SPI (DMTS), co-founder and scientific director (CSO) of CERES BRAIN THERAPEUTICS, has just obtained funding of nearly one million US dollars from the prestigious National Institute of Health for his project « Neuroprotective Strategy: Novel Purine Derivatives for Neonatal Hypoxia-ischemia ».
Jean-Luc Gennisson (BioMaps/SHFJ) coordinated, in partnership with the CEA-List (Sylvain Chatillon), the EchoBrain project (ATTRACT/H2020) aimed at adapting the digital tools developed by the List (CIVA platform) to significantly increase the quality of brain echography images, simple alternative compared to the methods (MRI, X-ray scanner) currently used for the diagnosis of strokes.
Coordinated by the Imagine Institute for Genetic Diseases, the ATRACTion program is based on a consortium of 11 academic and industrial partners, including SPI (DMTS), and aims to develop a precision medicine for patients with autoimmune and inflammatory diseases associated with primary immune deficiencies.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.